Report : North America Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)
The others segment by type is estimated to lead the market growth during the forecast period.
According to a new market research study of “North America Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type, Indication, Distribution Channel, and Country.” The North America carbapenem-based antibiotics market is expected to reach US$ 1,713.21 million by 2028 from US$ 1,244.59 million in 2021; it is estimated to grow at a CAGR of 4.7% from 2021-2028. The report highlights trends prevailing in the North America carbapenem-based antibiotics market and the factors driving market along with those that act as hindrances.
Gram-negative bacterial infections, such as urinary tract infection (UTI), pneumonia, bloodstream infections, wound or surgical site infections, and meningitis, are commonly acquired by patients during their hospital stays. These infections are generally known as hospital-acquired infections (HAI). Infections such as UTIs and pneumonia are common in patients admitted to intensive care units. According to the US National Healthcare Safety Network, 30% of HAIs are caused by gram-negative bacteria, ~45% are due to UTIs, and ~47% are by ventilator-associated pneumonia (VAP). The prevalence of infectious diseases caused by gram-negative bacteria is rapidly increasing.
In addition, gram-negative bacterial infections are resistant to multiple drugs and have developed better resistance to available antibiotics. Antimicrobial resistance (AMR) has become a global threat to modern medicine. Therefore, constant monitoring of emerging trends is required for the clinical isolates. A group of researchers in Latvia, Europe, has studied the progression of AMR for different gram-negative bacteria. As per the research article published by them in the MDPI journal in June 2021, carbapenem-based antibiotics such as Meropenem and Ertapenem were the most effective against gram-negative bacteria, showing 3% and 5.4% resistance rates, respectively. These antibiotics are globally accepted as a treatment for gram-negative bacteria. Therefore, it is estimated that the high demand for carbapenem-based antibiotics is likely to continue in the coming years.
According to the Centers for Disease Control and Prevention (CDC), the COVID-19 pandemic led to the rise in HAI cases in 2020. Hospital admissions have grown globally, which has increased the risk of VAP as a secondary infection for COVID-19 patients. This has resulted in fueled demand for carbapenem-based antibiotics, which is aiding the market significantly.
The North America carbapenem-based antibiotics market, by type, is segmented into meropenem, doripenem, imipenem, tebipenem, and others. Based on indication, the North America carbapenem-based antibiotics market has been segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. Based on distribution channel, the North America carbapenem-based antibiotics market has been segmented into retail pharmacies, online pharmacies, and hospital pharmacies. Geographically, the North America carbapenem-based antibiotics market is sub-segmented into U.S, Canada and Mexico.
ACS Dobfar S.p.A, Iterum Therapeutics plc, DAEWOONG PHARMACEUTICAL CO., LTD, Aurobindo Pharma Ltd, Gland Pharma Limited, Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Savior Lifetec, Pfizer Inc. and Spero Therapeutics are among the leading companies operating in the North America carbapenem-based antibiotics market.
Contact Person: Sameer Joshi
Email Id: email@example.com